Login to Your Account

Seattle Genetics Files BLA for Brentuximab, Eyes 'll Approval

By Catherine Shaffer

Tuesday, March 1, 2011
Barely three months after reporting its outstanding clinical results for brentuximab vedotin at the annual meeting of the American Society for Hematology (ASH) in December, Seattle Genetics Inc. submitted its biologics license application to the FDA, petitioning for an accelerated six-month approval timeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription